Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 10/20 | 0.65 |
| ▸ | NPY4R | P50391 | 8/20 | 0.65 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.65 |
| ▸ | NPY1R | P25929 | 8/20 | 0.65 |
| ▸ | CALCR | P30988 | 4/20 | 0.64 |
| ▸ | TFPI | P10646 | 3/20 | 0.62 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.60 |
| ▸ | EP300 | Q09472 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sstcipsgqpcpynenccsqsctykenengntvkrcd SCHEMBL29838759 | 0.97 | NPY2R (0.67) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| Savcipsgqpcpyskyccsgsctyktnengnsvqrcd SCHEMBL29838758 | 0.95 | NPY2R (0.69) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| Cipsgqpcpynenccsqsctfkenengntvkrcd SCHEMBL29993310 | 0.95 | NPY2R (0.64) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL31020752 | 0.91 | NPY2R (0.64) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL30906545 | 0.90 | MAPK8 (0.60) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL31182662 | 0.90 | NPY2R (0.68) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL30906388 | 0.90 | MAPK8 (0.61) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL30658298 | 0.90 | NPY2R (0.71) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL30712939 | 0.90 | EP300 (0.67) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL30432502 | 0.90 | NPY2R (0.67) | NPY2RNPY4RNPY5RNPY1RCALCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122012258-A | Metarhizium anisopliae engineering bacteria expressing spider toxic peptide Hv1a and application thereof in preventing and treating chilo suppressalis | 华中农业大学 | 2026-05-12 | — | — | CN | disclosed |
| US-20260042807-A1 | NEXT GENERATION ACTX PEPTIDES | Vestaron Corporation (US) | 2026-02-12 | — | — | US | disclosed |
| US-20250376494-A1 | INSECTICIDAL CYSTEINE RICH PEPTIDE EXPRESSION IN PLANTS | Vestaron Corporation (US) | 2025-12-11 | — | — | US | disclosed |
| EP-4622996-A1 | CONTROL OF NANOCAGE SELF-ASSEMBLY | King's College London (GB) | 2025-10-01 | — | — | EP | disclosed |
| US-12410218-B2 | Insecticidal peptide production and combination of cysteine rich peptides | Vestaron Corporation (US) | 2025-09-09 | — | — | US | disclosed |
| US-20250255310-A1 | ENHANCING PESTICIDAL ACTIVITY | UNIVERSITY OF DURHAM (GB) | 2025-08-14 | — | — | US | disclosed |
| US-20250115647-A1 | HV1 MODULATORS AND USES | UNIV CALIFORNIA (US) | 2025-04-10 | — | — | US | disclosed |
| WO-2025029828-A9 | OMEGA HEXATOXIN VARIANT PEPTIDES AND METHODS OF USE THEREOF | Vestaron Corporation (US) | 2025-03-13 | — | — | WO | disclosed |
| WO-2025029828-A1 | OMEGA HEXATOXIN VARIANT PEPTIDES AND METHODS OF USE THEREOF | Vestaron Corporation (US) | 2025-02-06 | — | — | WO | disclosed |
| EP-4498815-A1 | TOPICAL APPLICATION OF INSECTICIDAL RECOMBINANT TOXIN FUSION PROTEINS | University of Durham (GB) | 2025-02-05 | — | — | EP | disclosed |
| US-20230257427-A1 | INSECTICIDAL PEPTIDE PRODUCTION, PEPTIDE EXPRESSION IN PLANTS AND COMBINATIONS OF CYSTEINE RICH PEPTIDES | Vestaron Corporation (US) | 2023-08-17 | — | — | US | disclosed |
| US-11692016-B2 | High gene expression yeast strain | SUTERRA LLC | 2023-07-04 | — | — | US | disclosed |
| CN-116096236-A | Insecticidal combinations | 韦斯塔隆公司 | 2023-05-09 | — | — | CN | disclosed |
| US-20230002452-A1 | TARGETED MOSQUITOCIDAL TOXINS | BAYLOR UNIVERSITY (US) | 2023-01-05 | — | — | US | disclosed |
| US-11479583-B2 | Targeted mosquitocidal toxins | BAYLOR UNIVERSITY (US) | 2022-10-25 | — | — | US | disclosed |
| US-11472854-B2 | Insecticidal peptide production, peptide expression in plants and combinations of cysteine rich peptides | Vestaron Corporation (US) | 2022-10-18 | — | — | US | disclosed |
| WO-2022212863-A1 | LIPOSOME FORMULATIONS FOR PESTICIDE DELIVERY AND METHODS FOR PRODUCING AND USING THE SAME | Vestaron Corporation (US) | 2022-10-06 | — | — | WO | disclosed |
| US-20220289800-A1 | HV1 MODULATORS AND USES | UNIV CALIFORNIA (US) | 2022-09-15 | — | — | US | disclosed |
| WO-2022136440-A1 | PESTICIDAL HEXATOXIN POLYPEPTIDES AND METHODS OF USE THEREOF | SYNGENTA CROP PROTECTION AG (CH) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022136442-A2 | COMPOSITIONS COMPRISING CYCLOTIDES AND OTHER INSECTICIDAL PEPTIDES AND USES THEREOF | SYNGENTA CROP PROTECTION AG (CH) | 2022-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042807-A1 | NEXT GENERATION ACTX PEPTIDES | CRYAA, RNGTT, CALML3 | NPY2R 3324/4885NPY4R 3338/4885NPY5R 3579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.